MedPath

Assessment of oral Nicotinamide effects on serum phosphorus in hemodialysis patients in Imam Khomeini and Golestan hospitals of Ahvaz in 2010

Phase 3
Conditions
Hemodialysis patients (ESRD).
End-stage renal disease
Registration Number
IRCT138809172817N1
Lead Sponsor
Ahvaz Jondishapour University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
46
Inclusion Criteria

Age>18 years old, hemodialysis for more than 3 months, constant use of phosphate binder in recent two weeks, serum phosphorus>=5

Exclusion Criteria

liver disease or significant disturbance in liver function tests, active peptic ulcer, poor cooperation, severe diarrhea

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum phosphorus. Timepoint: week 0, 5 and 9 of the study. Method of measurement: serum phosphorus measurement by biochemistry autoanalyser.
Secondary Outcome Measures
NameTimeMethod
Serum iPTH. Timepoint: before and after the intervention. Method of measurement: Chemiluminescence iPTH measurement.;Serum lipids. Timepoint: before and after the intervention. Method of measurement: serum biochemistry by autoanalyser.
© Copyright 2025. All Rights Reserved by MedPath